Dexmedetomidine Sedation and Cardiopulmonary Bypass

• Status: Completed
• Trial end date: 2016-09-01
• Target enrollment: 0
• Participant gender: All

Summary

Dexmedetomidine is a unique sedative anesthetic agent that allows accurate control of the depth of sedation and provides analgesia, cardio protection, renal protection, and neuroprotection without causing respiratory depression. It is an alpha 2-adrenoreceptor agonist that modulates the release of catecholamines from the central and autonomic nervous systems. When patients sedated by dexmedetomidine are allowed to become responsive, they are calm and cooperative (1). No other sedative agent has this feature, and sedated patients frequently awaken in a confused state. Investigators are conducting this study project to compare between dexmedetomidine based and propofol based anesthetic techniques with regard to hemodynamic changes, stress hormone release as well as cytokines in patients undergoing CPB for coronary revascularization.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Assiut University
• Treatments: Dexmedetomidine; Propofol

Criteria

Inclusion Criteria:

• patients scheduled for elective coronary revascularization surgery with cardiopulmonary bypass

Exclusion Criteria:

• Severely impaired left ventricular function (ejection fraction <40%)

• Valvular heart disease

• Low cardiac output syndrome

• Uncontrolled rapid atrial fibrillation

• On plavix less than one week

• Severe systemic non-cardiac disease

• Infectious disease

• Poorly controlled diabetes mellitus

• patients on corticosteroids or other immunosuppressive treatment